SCHEMBL3560003

SCHEMBL3560003

CCOC(=O)C(N)c1cc(C)nc(-n2ccnc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPK1 P28482 2/20 0.43
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MITF O75030 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NOS2 P35228 4/20 0.41
NOS1 P29475 1/20 0.38
CD38 P28907 3/20 0.38
HTT P42858 2/20 0.36
CXCR2 P25025 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559045 0.83 ALDH1A1 (0.41) TSHRKDM4EMAPK1ATMTDP1
SCHEMBL3559041 0.81 NOS2 (0.44) TSHRKDM4EMAPK1ATMTDP1
SCHEMBL3559869 0.79 TSHR (0.43) TSHRKDM4EMAPK1ATMTDP1
SCHEMBL25485897 0.78 KDM4E (0.45) TSHRKDM4EMAPK1ATMTDP1
SCHEMBL13037152 0.74 ALDH1A1 (0.42) TSHRKDM4EMAPK1ATMTDP1
SCHEMBL3560941 0.74 KDM4E (0.45) TSHRKDM4EMAPK1ATMTDP1
SCHEMBL13037188 0.72 LMNA (0.50) TSHRKDM4EMAPK1TDP1MEN1
SCHEMBL3566113 0.71 CD38 (0.45) TSHRMAPK1NOS2CD38CYP1A2
SCHEMBL9521243 0.71 SMN1; SMN2 (0.42) TSHRKDM4EMAPK1ATMTDP1
SCHEMBL3558347 0.71 NOS2 (0.55) TSHRKDM4EMAPK1ATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 TSHR 788/4885KDM4E 1567/4885MAPK1 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.